The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global blood culture test market reached a value of US$ 4.2 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 9% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A blood culture test refers to a medical procedure that is conducted to diagnose bacterial, fungal and mycobacterial infections. It is performed for the identification of various microorganisms in the blood sample and for preventing the development of sepsis conditions. The results of the culture test can aid in determining the specific pathogens that are causing the infection in the blood and possible ways to combat it. It utilizes products including blood culture media, assay kits, reagents, and blood culture accessories, and instruments such as automated blood culture systems and supporting laboratory equipment.
The increasing prevalence of chronic and infectious diseases across the globe is one of the key factors driving the growth of the market. Furthermore, the growing geriatric population that is more susceptible to sepsis and other medical ailments is also providing a boost to the market growth. Additionally, the growing demand for blood culture tests to analyze specimens, owing to the current outbreak of the COVID-19 pandemic, is acting as another major growth-inducing factor. Laboratories, diagnostic centers and other healthcare institutes are now increasingly using these tests for detecting the presence of antibodies in the blood and identifying and isolating the infected individuals. Other factors, including the rising health consciousness among the masses, improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood culture test market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on testing medthod, product, technology, application and end-user.
Breakup by Testing Method:
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Beckman Coulter (Danaher Corporation), BD (Becton, Dickinson and Company), Biomérieux SA, Bruker Corporation, Cepheid Inc. (Danaher Corporation), Luminex Corporation, Merck Group, Siemens Healthineers AG, Roche Diagnostics, T2 Biosystems, Thermo Fisher Scientific Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Testing Method, Product, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Beckman Coulter (Danaher Corporation), BD (Becton, Dickinson and Company), Biomérieux SA, Bruker Corporation, Cepheid Inc. (Danaher Corporation), Luminex Corporation, Merck Group, Siemens Healthineers AG, Roche Diagnostics, T2 Biosystems and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at